Abstract: Furthermore, the present invention relates to a composition, a method of binding a zwitterionic nanoparticle and the use of a zwitterionic nanoparticle.

Abstract: The present invention relates to nanoparticles for the targeted delivery of antigen to liver cells, in particular, liver sinusoidal endothelial cells (LSEC) and/or Kupffer cells, and for the in vivo generation of regulatory T cells, notably CD4+CD25+FOXP3+ regulatory T cells (Treg). The invention provides pharmaceutical compositions and methods for the prevention and treatment of autoimmune diseases, allergies or other chronic inflammatory conditions, and for generation of regulatory T cells. The nanoparticles used in the invention comprise a) a micelle comprising an amphiphilic polymer rendering the nanoparticle water-soluble, and b) a peptide comprising at least one T cell epitope associated with the outside of the micelle. The micelle may or may not comprise a solid hydrophobic core.

Abstract: The present invention relates to a zwitterionic nanoparticle, the zwitterionic nanoparticle comprising at least one nanoparticle and a zwitterionic case enclosing the nanoparticle. Furthermore, the present invention relates to a composition, a method of binding a zwitterionic nanoparticle and the use of a zwitterionic nanoparticle.

Abstract: The present invention relates to a zwitterionic nanoparticle, the zwitterionic nanoparticle comprising at least one nanoparticle and a zwitterionic case enclosing the nanoparticle. Furthermore, the present invention relates to a composition, a method of binding a zwitterionic nanoparticle and the use of a zwitterionic nanoparticle.

Abstract: The present invention relates to a composition, comprising at least one micelle in non-aqueous solution, wherein the micelle encapsules one or more nanoparticle(s) and wherein the micelle comprises a cross-linked hydrophilic shell. Furthermore, the present invention relates to the use of such a composition and to methods for providing such a composition.

Abstract: The present invention relates to a composition, comprising at least one micelle in non-aqueous solution, wherein the micelle encapsules one or more nanoparticles. Furthermore, the present invention relates to the use of such a composition and to methods for providing such a composition.

Abstract: The present invention relates to a process for the continuous preparation of core-shell nanoparticles, comprising a core of a core material, preferably of a semiconductor material, and a shell of a shell material, preferably of a semiconductor material, wherein selected starling materials for the shell material are mixed with a dispersion of nanoparticles of the core material and are passed continuously through a reaction zone of a tubular reactor, and other starting materials for the shell material are fed to the reaction zone of the tubular reactor at two or more locations, preferably via a tubular membrane, and the starting materials for the shell material react in the reaction zone to form a shell around the nanoparticles of the core material. The invention also relates to the tubular reactor with the membrane and its use for the continuous synthesis of core-shell nanoparticles.

Abstract: The present invention relates to a process for the continuous preparation of core-shell nanoparticles, comprising a core of a core material, preferably of a semiconductor material, and a shell of a shell material, preferably of a semiconductor material, wherein selected starting materials for the shell material are mixed with a dispersion of nanoparticles of the core material and are passed continuously through a reaction zone of a tubular reactor, and other starting materials for the shell material are fed to the reaction zone of the tubular reactor at two or more locations, preferably via a tubular membrane, and the starting materials for the shell material react in the reaction zone to form a shell around the nanoparticles of the core material. The invention also relates to the tubular reactor with the membrane and its use for the continuous synthesis of core-shell nanoparticles.

Abstract: The present invention relates to nanoparticles for the targeted delivery of antigen to liver cells, in particular, liver sinusoidal endothelial cells (LSEC) and/or Kupffer cells, and for the in vivo generation of regulatory T cells, notably CD4+CD25+FOXP3+ regulatory T cells (Treg). The invention provides pharmaceutical compositions and methods for the prevention and treatment of autoimmune diseases, allergies or other chronic inflammatory conditions, and for generation of regulatory T cells. The nanoparticles used in the invention comprise a) a micelle comprising an amphiphilic polymer rendering the nanoparticle water-soluble, and b) a peptide comprising at least one T cell epitope associated with the outside of the micelle. The micelle may or may not comprise a solid hydrophobic core.

Abstract: The present invention relates to nanoparticles for the targeted delivery of antigen to liver cells, in particular, liver sinusoidal endothelial cells (LSEC) and/or Kupffer cells, and for the in vivo generation of regulatory T cells, notably CD4+CD25+FOXP3+ regulatory T cells (Treg). The invention provides pharmaceutical compositions and methods for the prevention and treatment of autoimmune diseases, allergies or other chronic inflammatory conditions, and for generation of regulatory T cells. The nanoparticles used in the invention comprise a) a micelle comprising an amphiphilic polymer rendering the nanoparticle water-soluble, and b) a peptide comprising at least one T cell epitope associated with the outside of the micelle. The micelle may or may not comprise a solid hydrophobic core.

Abstract: The present invention relates to a composition, comprising at least one micelle in non-aqueous solution, wherein the micelle encapsules one or more nanoparticles. Furthermore, the present invention relates to the use of such a composition and to methods for providing such a composition.

Abstract: The present invention relates to a composition, comprising at least one micelle in non-aqueous solution, wherein the micelle encapsules one or more nanoparticle(s) and wherein the micelle comprises a cross-linked hydrophilic shell. Furthermore, the present invention relates to the use of such a composition and to methods for providing such a composition.

Abstract: The present invention relates to a process for the continuous preparation of core-shell nanoparticles, comprising a core of a core material, preferably of a semiconductor material, and a shell of a shell material, preferably of a semiconductor material, wherein selected starting materials for the shell material are mixed with a dispersion of nanoparticles of the core material and are passed continuously through a reaction zone of a tubular reactor, and other starting materials for the shell material are fed to the reaction zone of the tubular reactor at two or more locations, preferably via a tubular membrane, and the starting materials for the shell material react in the reaction zone to form a shell around the nanoparticles of the core material. The invention also relates to the tubular reactor with the membrane and its use for the continuous synthesis of core-shell nanoparticles.

Abstract: An apparatus (10) and a method (200) for the manufacture of nanoparticles. The apparatus and the method allows for the nucleation and growth of nanoparticles at independent temperatures. The independent temperatures allow for the growth of nanoparticles in a controlled environment avoiding spontaneous nucleation and allowing particle sizes to be controlled and facilitating the manufacture of particles of a substantially uniform size. Furthermore the apparatus (10) allows for the manufacture of core-shell nanoparticles and core-shell-shell nanoparticles.

Abstract: The present invention relates to nanoparticles for the targeted delivery of antigen to liver cells, in particular, liver sinusoidal endothelial cells (LSEC) and/or Kupffer cells, and for the in vivo generation of regulatory T cells, notably CD4+CD25+FOXP3+ regulatory T cells (Treg). The invention provides pharmaceutical compositions and methods for the prevention and treatment of autoimmune diseases, allergies or other chronic inflammatory conditions, and for generation of regulatory T cells. The nanoparticles used in the invention comprise a) a micelle comprising an amphiphilic polymer rendering the nanoparticle water-soluble, and b) a peptide comprising at least one T cell epitope associated with the outside of the micelle. The micelle may or may not comprise a solid hydrophobic core.

Abstract: A method for the manufacture of a III-V compound in the form of nanoparticles, such as those used in semi-conductors. The reaction proceeds at atmospheric pressure in a reaction solution by the reaction of a III compound source and a V compound source. The reaction proceeds in solvent of high boiling point. The solvent contains a stabilizer and a base. The manufactured III-V compound is precipitated from the reaction solution, isolated, purified and analyzed.

Abstract: The present invention relates to the field of in vivo determination of enzyme activity. It also allows visualization of organisms, organs, tissues and cells. In particular, the present invention provides a method of in vivo visualization and a composition suitable for in vivo determination and/or visualization of enzyme activity by methods such as Magnetic Resonance Imaging, also called Magnetic Resonance Tomography (MRI or MRT), or Magnetic Particle Imaging (MPI). In particular, the activity of the enzyme lipoprotein lipase affects the signals received and allows conclusions on the lipid metabolism of an organism, an organ system, an organ, a tissue and a cell of interest, This method can be employed, e.g., for diagnosis of cardiac disorders, of tumor prognosis and of disorders of the lipid metabolism. The composition used comprises superparamagnetic iron oxide nanocrystals (SPIO) incorporated in the core of lipid micelles designated nanosomes.

Abstract: The field of the present invention relates to the stabilisation of nanoparticles in aqueous dispersion and, in particular, the stabilisation of nanoparticles by encapsulating the nanoparticles in a micellular combination. The field of the present invention further relates to a micellular combination of nanoparticles and a method of manufacture of the micellular combination and uses thereof. In a first aspect the present disclosure teaches a micellular combination that allows the stable dispersion of nanoparticles into aqueous environment. The micellular combination comprises at least one nanoparticle in a core of the micellular combination. A plurality of surfactants is co-assembled with a plurality of hydrophobic ligands on the surface of the nanoparticle in such a way that the hydrophilic part of the surfactant forms a hydrophilic shell around the core of the micellular combination.

Abstract: A T1 blood pool contrast agent comprising very small iron oxide nanoparticles are coated with poly(ethylene glycol) (PEG) based ligands. Core size and length of the PEG chain were optimized according to stability, relaxometric properties, cytotoxicity and unspecified cell uptake.

Abstract: The present invention relates to the manufacture of triblock polymer ligands (30) and nanoparticle complexes (80). The nanoparticle complexes (80) comprise a capped nanoparticle (10) and the triblock polymer ligand (30). The triblock polymer ligand (30) consists of a binding polymer (40), a hydrophobic polymer (50) and a hydrophilic functionalisable polymer (60). The binding polymer (40) attaches to the capped nanoparticle (10).